山东医药
山東醫藥
산동의약
SHANDONG MEDICAL JOURNAL
2014年
29期
8-11
,共4页
陈超%郭雪兴%刘军权%陈剑群
陳超%郭雪興%劉軍權%陳劍群
진초%곽설흥%류군권%진검군
肝肿瘤%塞来昔布%自然杀伤细胞
肝腫瘤%塞來昔佈%自然殺傷細胞
간종류%새래석포%자연살상세포
liver neoplasms%celecoxib%natural killer cells
目的:观察塞来昔布联合NK细胞对裸鼠人肝癌细胞SMMC-7721皮下移植瘤生长的影响,并探讨其可能的作用机制。方法选择裸鼠40只,制备人肝癌细胞SMMC-7721移植瘤模型,随机分为对照组、NK细胞组、塞来昔布组及联合干预组各10只。 NK细胞组瘤内注射NK细胞悬液0.6 mL,每7 d注射1次,共注射5次;塞来昔布组从接种后第3天起给予塞来昔布100 mg/kg灌胃,每天1次,连续35 d;联合干预组同时给予塞来昔布和NK细胞,给药剂量及途径与单用组相同;对照组灌胃和瘤内注射等量生理盐水。35 d后切取移植瘤组织计算体积,称取瘤质量,并计算抑瘤率;TUNEL法评价肿瘤细胞凋亡情况,免疫组化法检测肿瘤内VEGF、Bax、Bcl-2、caspase-3、Ki-67、NF-κB的阳性表达。结果联合干预组移植瘤体积、肿瘤质量均明显低于单用组( P均<0.05),抑瘤率、凋亡指数明显高于单用组( P均<0.05)。联合干预组移植瘤中VEGF、Bcl-2、NF-κB、Ki-67表达明显低于单用组( P均<0.05),Bax、caspase-3表达明显高于单用组(P均<0.05)。结论塞来昔布联合NK细胞可明显抑制裸鼠人肝癌细胞SMMC-7721皮下移植瘤的生长;其作用机制可能是通过促进凋亡级联通路上Bax、caspase-3的表达,抑制VEGF、Bcl-2、NF-κB、Ki-67的表达而实现。
目的:觀察塞來昔佈聯閤NK細胞對裸鼠人肝癌細胞SMMC-7721皮下移植瘤生長的影響,併探討其可能的作用機製。方法選擇裸鼠40隻,製備人肝癌細胞SMMC-7721移植瘤模型,隨機分為對照組、NK細胞組、塞來昔佈組及聯閤榦預組各10隻。 NK細胞組瘤內註射NK細胞懸液0.6 mL,每7 d註射1次,共註射5次;塞來昔佈組從接種後第3天起給予塞來昔佈100 mg/kg灌胃,每天1次,連續35 d;聯閤榦預組同時給予塞來昔佈和NK細胞,給藥劑量及途徑與單用組相同;對照組灌胃和瘤內註射等量生理鹽水。35 d後切取移植瘤組織計算體積,稱取瘤質量,併計算抑瘤率;TUNEL法評價腫瘤細胞凋亡情況,免疫組化法檢測腫瘤內VEGF、Bax、Bcl-2、caspase-3、Ki-67、NF-κB的暘性錶達。結果聯閤榦預組移植瘤體積、腫瘤質量均明顯低于單用組( P均<0.05),抑瘤率、凋亡指數明顯高于單用組( P均<0.05)。聯閤榦預組移植瘤中VEGF、Bcl-2、NF-κB、Ki-67錶達明顯低于單用組( P均<0.05),Bax、caspase-3錶達明顯高于單用組(P均<0.05)。結論塞來昔佈聯閤NK細胞可明顯抑製裸鼠人肝癌細胞SMMC-7721皮下移植瘤的生長;其作用機製可能是通過促進凋亡級聯通路上Bax、caspase-3的錶達,抑製VEGF、Bcl-2、NF-κB、Ki-67的錶達而實現。
목적:관찰새래석포연합NK세포대라서인간암세포SMMC-7721피하이식류생장적영향,병탐토기가능적작용궤제。방법선택라서40지,제비인간암세포SMMC-7721이식류모형,수궤분위대조조、NK세포조、새래석포조급연합간예조각10지。 NK세포조류내주사NK세포현액0.6 mL,매7 d주사1차,공주사5차;새래석포조종접충후제3천기급여새래석포100 mg/kg관위,매천1차,련속35 d;연합간예조동시급여새래석포화NK세포,급약제량급도경여단용조상동;대조조관위화류내주사등량생리염수。35 d후절취이식류조직계산체적,칭취류질량,병계산억류솔;TUNEL법평개종류세포조망정황,면역조화법검측종류내VEGF、Bax、Bcl-2、caspase-3、Ki-67、NF-κB적양성표체。결과연합간예조이식류체적、종류질량균명현저우단용조( P균<0.05),억류솔、조망지수명현고우단용조( P균<0.05)。연합간예조이식류중VEGF、Bcl-2、NF-κB、Ki-67표체명현저우단용조( P균<0.05),Bax、caspase-3표체명현고우단용조(P균<0.05)。결론새래석포연합NK세포가명현억제라서인간암세포SMMC-7721피하이식류적생장;기작용궤제가능시통과촉진조망급련통로상Bax、caspase-3적표체,억제VEGF、Bcl-2、NF-κB、Ki-67적표체이실현。
Objective To evaluate the inhibitory effect and its mechanism of celecoxib combined with NK cells on the growth of implanted human liver caner cell line SMMC-7721 in nude mice.Methods Forty nude mice were inoculated the hepatoma cell line SMMC-7721, and then were randomly divided into the control group , NK cells group, celecoxib group and combined intervention group with 10 rats in each group.in the NK cells group, the mice were intratumorally injected NK cell suspension 0.6 mL, every 7 d for one time, for 5 times;in the celecoxib group, from the third day after inocula-tion, the mice were treated with celecoxib 100 mg/kg orally, 1 time a day for 35 days;in the combined intervention group , mice were given celecoxib and NK cells , whose dosage and way were the same as that of the single group; in the control group, mice were given oral and intratumoral injection of normal saline .Thirty-five days later , the mice′s tumors were ex-cised for further analysis .The tumors were weighed and the tumor inhibitory rate was calculated .Apoptosis was measured by using a terminal deoxynucleotidyl transferase-mediated nick-end labeling ( TUNEL) assay.The protein levels of vascular endothelial growth factor (VEGF), Bax, Bcl-2, caspase-3, Ki-67 and NF-κB were detected by immunohistochemistry . Results The tumor volume , tumor mass and apoptosis index of the combined intervention group were significantly lower than those of the NK cells group and celecoxib group (all P<0.05).The tumor inhibition rate was 28.84% in the NK cells group and 50.42%in the celecoxib group which was significantly lower than that 87.59%in the combined interven-tion group.The expression of VEGF, Bcl-2, NF-κB and Ki-67 was significantly lower, but the expression of Bax and caspase-3 was significantly higher in the combined intervention group than that of the other single groups (all P<0.05).Conclusion Celecoxib combined with NK cells can induce the apoptosis of SMMC-7721 cells and inhibit the growth of xenografts, whose mechanism may be related to inhibiting the expression of VEGF , Bcl-2, NF-κB, Ki-67 and promoting the expression of Bax and caspase-3.